| | | | | | | | | | |
|
Dockets Management
|
| Dockets Entered On
July 20, 2006
Table of Contents
|
|
|
|
|
|
|
| Docket #
|
| Title
|
|
|
|
|
| 1997S-0162
|
| 30-Day Structure Function Claim Notification Letters Dietary
|
|
|
| 1998C-0431
|
| Synthetic Iron Oxide
|
|
|
| 1999F-4372
|
| National Fisheries Institute and the Louisiana Dep of Agricu
|
|
|
| 2001P-0345
|
| Listing the color additive yellow #5 for use in food/Drug
|
|
|
| 2003N-0076
|
| Food Labeling: Trans Fatty Acids in Nutrition Labeling; Consumer research to consider possible footnote statements
|
|
|
| 2005P-0411
|
| Seeking FDA Actions to Counter Flagrant Violations of the Law by Pharmacies Compounding Bio-Identical Hormone Replacement Therapy Drugs
|
|
|
| 2005P-0456
|
| Determine that the discontinued formulation Zosyn (piperacillin and tazobactam for injection), was not discontinued for safety and efficacy reasons
|
|
|
| 2006D-0108
|
| Guidance for Industry: Informed Consent Recommendations for Source Plasma Donors Participating in Plasmapheresis and Immunization Programs
|
|
|
| 2006D-0246
|
| Manufactured Food Regulatory Program Standards
|
|
|
| 2006N-0107
|
| FDA-Regulated Products Containing Nanotechnology Materials
|
|
|
| 2006N-0247
|
| Agency Information Collection Activities; Proposed Collection; Comment Request; Medical Device User Fee Cover Sheet
|
|
|
| 2006P-0049
|
| reduce the public health risks associated with the use of drugs manufactured or processed at foreign facilities
|
|
|
| 2006P-0123
|
| Request that all applicants for fentanyl transdermal systems conduct a study to support the safety of their fentanyl transdermal products
|
|
|
| 2006P-0124
|
| Stay any approvals of an Abbreviated New Drug Application (ANDA) for Vancocin Capsules
|
|
|
| 2006P-0151
|
| Stay the current approvable letter with conditions of any and all Premarket Applications for silicone gel-filled breast implants
|
|
|
| 2006P-0173
|
| Request approval of any abbreviated new drug application relying on Zosyn (piperacillin and tazobactam for injection) as its reference product be contingent upon the proposed product
|
|
|
| 1997S-0162
|
| 30-Day Structure Function Claim Notification Letters Dietary
|
|
|
| LET 17981
|
| Weleda Inc
|
| Vol #:
|
| 165
|
|
|
| LET 17982
|
| Swanson Health Products
|
| Vol #:
|
| 165
|
|
|
| LET 17983
|
| Source Naturals
|
| Vol #:
|
| 165
|
|
|
| LET 17984
|
| Perrigo Company of South Carolina
|
| Vol #:
|
| 165
|
|
|
| LET 17985
|
| Perrigo Company of South Carolina
|
| Vol #:
|
| 165
|
|
|
| LET 17986
|
| Perrigo Company of South Carolina
|
| Vol #:
|
| 165
|
|
|
| LET 17987
|
| Perrigo Company of South Carolina
|
| Vol #:
|
| 165
|
|
|
| LET 17988
|
| Natura Therapeutics Inc
|
| Vol #:
|
| 165
|
|
|
| LET 17989
|
| New Century Company
|
| Vol #:
|
| 165
|
|
|
| LET 17990
|
| Metagenics
|
| Vol #:
|
| 165
|
|
|
| 1998C-0431
|
| Synthetic Iron Oxide
|
|
|
| NFR 2
|
| FDA
|
| Vol #:
|
| 1
|
|
|
| 1999F-4372
|
| National Fisheries Institute and the Louisiana Dep of Agricu
|
|
|
| EMC 476
|
| Form Letter
|
| Vol #:
|
| 14
|
|
|
| EMC 477
|
| R. Grover
|
| Vol #:
|
| 15
|
|
|
| EMC 478
|
| M. Buckner
|
| Vol #:
|
| 15
|
|
|
| EMC 479
|
| Y. Waters
|
| Vol #:
|
| 15
|
|
| | | | | | | | |
|
|
| EMC 3316
|
| M. Malone
|
| Vol #:
|
| 176
|
|
|
| EMC 3317
|
| C. Macdonald
|
| Vol #:
|
| 176
|
|
|
| EMC 3318
|
| E. Treneer
|
| Vol #:
|
| 176
|
|
|
| EMC 3319
|
| N. Slowinski
|
| Vol #:
|
| 176
|
|
|
| EMC 3320
|
| J. Hutson
|
| Vol #:
|
| 176
|
|
|
| EMC 3321
|
| R. Way
|
| Vol #:
|
| 176
|
|
|
| 2005P-0456
|
| Determine that the discontinued formulation Zosyn (piperacillin and tazobactam for injection), was not discontinued for safety and efficacy reasons
|
|
|
| C 7
|
| Wyeth Pharmaceuticals
|
| Vol #:
|
| 2
|
|
|
| 2006D-0108
|
| Guidance for Industry: Informed Consent Recommendations for Source Plasma Donors Participating in Plasmapheresis and Immunization Programs
|
|
|
| EC 1
|
| PPTA
|
| Vol #:
|
| 1
|
|
|
| EMC 1
|
| Plasma Protein Therapeutics Association (PPTA)
|
| Vol #:
|
| 1
|
|
|
| 2006D-0246
|
| Manufactured Food Regulatory Program Standards
|
|
|
| GDL 1
|
| Guidance
|
| Vol #:
|
| 1
|
|
|
| NAD 1
|
| FDA
|
| Vol #:
|
| 1
|
|
|
| 2006N-0107
|
| FDA-Regulated Products Containing Nanotechnology Materials
|
|
|
| EC 7
|
| Project on Emerging Nanotechnologies/Wilson Center
|
| Vol #:
|
| 2
|
|
|
| 2006N-0247
|
| Agency Information Collection Activities; Proposed Collection; Comment Request; Medical Device User Fee Cover Sheet
|
|
|
| C 1
|
| AMEDICA
|
| Vol #:
|
| 1
|
|
|
| 2006P-0049
|
| reduce the public health risks associated with the use of drugs manufactured or processed at foreign facilities
|
|
|
| LET 1
|
| FDA/CDER to Synthetic Organic Chemical Manufacturers Association's
|
| Vol #:
|
| 1
|
|
|
| 2006P-0123
|
| Request that all applicants for fentanyl transdermal systems conduct a study to support the safety of their fentanyl transdermal products
|
|
|
| C 4
|
| PriCara, Unit of Ortho-McNeil
|
| Vol #:
|
| 1
|
|
|
| 2006P-0124
|
| Stay any approvals of an Abbreviated New Drug Application (ANDA) for Vancocin Capsules
|
|
|
| C 2
|
| Memorial Hospital of Rhode Island
|
| Vol #:
|
| 1
|
|
|
| 2006P-0151
|
| Stay the current approvable letter with conditions of any and all Premarket Applications for silicone gel-filled breast implants
|
|
|
| EC 630
|
| Ms. Nicole Chantee
|
| Vol #:
|
| 3
|
|
|
| EC 631
|
| Ms. Electra Kaczorowski
|
| Vol #:
|
| 3
|
|
|
| EC 632
|
| Women's Bioethics Project
|
| Vol #:
|
| 3
|
|
|
| 2006P-0173
|
| Request approval of any abbreviated new drug application relying on Zosyn (piperacillin and tazobactam for injection) as its reference product be contingent upon the proposed product
|
|
|
|
|
|
| SUP 2
|
| Wyeth Pharmaceuticals
|
| Vol #:
|
| 1
|
|